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NOTE
KISS AND MAKE-UP: A NEED FOR
CONSOLIDATION OF FDA AND
COSMETIC INDUSTRY REGULATION
PROGRAMS
Deborah E. Masont
INTRODUCTION
The Food and Drug Administration (FDA) protects all consumers
in the U.S. "with a broad umbrella of safeguards that enables them to
go about their daily business without worries about the safety of the
myriad products FDA regulates."' Cosmetics are among the products
regulated by the FDA.2 The Federal Food, Drug, and Cosmetic Act
(the FDA Act) is the law regulating food and drug safety in the U.S.
This law is intended to "assure consumers ... that cosmetics are safe
and made from appropriate ingredients; and that all labeling and pack-
aging is truthful, informative, and not deceptive. 3 Despite the law's
intended assurances, John E. Bailey, director of the FDA's Division of
Color and Cosmetics, said, "[m]ost cosmetics contain ingredients that
are promoted with exaggerated claims of beauty or long-lasting ef-
fects to create an image .... Image is what the cosmetic industry
sells through its products, and it's up to the consumer to believe it or
not.
,A
t J.D. Candidate 2008, Case Western Reserve University School of Law
1 U.S. FOOD & DRUG ADMIN., U.S. DEP'T OF HEALTH & HUMAN SERVS.,
FDA's GROWING RESPONSIBILITIES FOR THE YEAR 2001 AND BEYOND 1 (2001),
http://www.fda.gov/oc/opacombudgetbro/budgetbro.htnl [hereinafter FDA'S
GROWING RESPONSIBILITIES].
2 Id. at 2.
3 Ctr. for Drug Evaluation & Research, U.S. Food & Drug Admin., Regula-
tions and Policies and Procedures for Postmarketing Surveillance Programs
http://www.fda.gov/cder/regulatory/applications/Postmarketing/regspostmarket.htm
(last visited Sept. 28, 2007).
4 Judith E. Foulke, Cosmetic Ingredients: Understanding the Puffery, FDA
CONSUMER, May 1992, http://www.fda.gov/fdac/reprints/puffery.html (quotations
omitted).
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A survey conducted in 2004 by the National Consumers League
revealed that six out of ten adults believe that the FDA tests anti-aging
[one form of cosmetic product] for safety and efficacy, when in real-
ity, this is untrue.5 By inadequately regulating the cosmetic industry,
the FDA, a body whose mission statement proclaims responsibility
for, "protecting the public health by assuring the safety, efficacy, and
security of human and veterinary drugs, biological products, medical
devices, our nation's food supply, cosmetics, and products that emit
radiation,"6 is failing the American public by its inadequate regulation
of the cosmetic industry.
The FDA requires drugs undergo thorough testing before the
agency will consider approving them and placing them on the mar-
ket.7 Cosmetic products, on the other hand, do not require extensive
testing or pre-market approval by the FDA.8 As such, "many cos-
metic companies avoid testing the ingredients in their products," or
avoid publicizing the results of these tests in an effort to avoid the
labeling requirements for products meeting the definition of a "drug."9
This is especially problematic since some scientists believe "that some
of the chemicals found in commonly used health and beauty products
can, in sufficient quantity, cause cancer, birth defects or disrupt hor-
mone function."'10 Dibutyl phthalates, for example, a chemical used to
soften plastics and found in nail polish and other cosmetic products,
have been linked to development problems in the male genitals of
humans and rats." The drug versus cosmetic controversy has led
some scientists and researchers to call for the creation of a new cate-
gory, "cosmeceuticals," "to allow the necessary testing of the products
for patient use, while at the same time protecting the interests of the
cosmetic companies."' 2
5 Erika Kawalek, Artfully Made-Up, LEGAL AnF., Nov.-Dec. 2005, at 54,
55. 6 U.S. Food & Drug Admin., FDA's Mission Statement,
http://www.fda.gov/opacom/morechoices/mission.html (last visited Sept. 28, 2007).
7 Melissa C. Lazarus & Leslie S. Baumann, The Use of Cosmeceutical
Moisturizers, 14 DERMATOLOGIC THERAPY 200, 200 (2001).
8 id.
9 Id.
10 Lisa Stiffler, Putting on Your Face Can Become Pretty Ugly: Chemicals in
Cosmetics Linked to Cancer, Birth Defects, SEATTLE POST-INTELLIGENCER, Nov. 6,
2006, at Al, available at
http://seattlepi.nwsource.com/health/291217_cosmetics06.html.
"1 See id. (explaining that some nail polish companies have agreed to phase
out dibutyl phthalate, a chemical that may be a human reproductive toxin).
12 Lazarus & Baumann, supra note 7 at 200.
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Those calling for the new category cite drugs on the market that
are also available in cosmetic form, including lactic acid (known as
Lac Hydrin in prescription form), and the drug Regranex.13 Both
drugs are in over the counter cosmetic products. 14 The call for the
creation of this hybrid category by various consumer groups claims
that in order to learn more about the healing powers of these ingredi-
ents, "[c]osmetic companies should be encouraged to perform these
studies on their products, despite the fact that it may cause them to
lose their product's cosmetic label."1 5 The FDA has not recognized
the cosmeceutical category, therefore no FDA-approved definition
exists; however, the industry defines cosmeceuticals as "a cosmetic
product that claims to or has been found to have biologic activity."'
16
In January, 2005, FDA District Director B. Belinda Collins issued
a warning letter to Basic Research, the marketer and distributor of
numerous cosmetic products including StriVectin-SD.17 Collins wrote
the letter in reference to Basic Research's marketing and distribution
of StriVectin-SD, StriVectin-SD Eye Cream, Dermalin-Apg, Mam-
ralinAra, and TestroGel; the letter described some of the claims made
by Basic Research about these products, including: "'Clinically
Proven to Dramatically Reduce the Appearance of Existing Stretch
Mark Length, Depth, Texture, and Discoloration'; 'Optimum Glyco-
saminoglycan and Collagen Synthesis'; 'Better than Botox®?'; and
'Superior wrinkle-reducing properties of a patented oligo-peptide."'
8
The letter lists nearly 40 other claims made for Basic Research prod-
ucts which would rightfully categorize the products as drugs. 19 Be-
cause of these claims, StriVectin-SD and the other Basic Research
Products were wrongfully labeled cosmetics. 20 However, by the time
Collins issued a warning letter, StriVectin-SD's 2005 earnings were
already on their way to the $100 million mark, "a sign of FDA inac-
tion and consumer confusion.'
FDA warning letters are effective in curtailing FDA Act viola-
tions once discovered. However, the FDA does not have the re-
13 Id. at 206.
14 Id.
15 Id. (emphasis added).
16 Id. at 200.
7 Kawalek, supra note 5, at 57.
18 Id. (quoting Letter from B. Belinda Collins, District Director, U.S. Food &
Drug Admin., to Dennis Gay, Chief Executive Officer, Basic Research (Jan. 20,
2005), available at http://www.fda.gov/foi/warningletters/archive/g5l95d.htm).
19 Id.
20 See id. (reporting that Basic Research's questionable marketing practices
caused the FDA to issue a warning letter).
21 Id.
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sources to seek out every violation, issue a warning letter, and subse-
quently protect consumers from the misleading advertisements and
potentially unsafe products. "For every FDA warning letter [sent],
thousands of misbranded cosmetics... slip by."22 Had Basic Research
identified these products as drugs, the FDA would have required
product and ingredient testing, for both safety and efficacy, prior to
approving the products. By labeling the items as cosmetic products,
however, Basic Research was able to sell them across the U.S., mak-
ing unsubstantiated claims about both safety and efficacy, without any
FDA oversight or regulation. Consumers purchased StriVectin-SD
and other Basic Research Products, relying on the statements made
about these product. They were misled and unprotected. As a result
of the issues exemplified by this type of violation, an improved sys-
tem of oversight is necessary to adequately protect American consum-
ers.
This Note identifies the dichotomy between drug and cosmetic
products and calls attention to the cosmetic industry's current self-
regulation programs. This Note also explores more stringent systems
of review in countries outside the U.S., as well as in individual U.S.
states while identifying the need for more stringent safety regulations
in the U.S. on cosmetic products and the ingredients used in those
products.
The purpose of this Note is to suggest possible regulatory changes
which, if enacted, would increase the safety testing of cosmetic ingre-
dients and products. This Note will also outline the roles of both the
FDA and the cosmetic industry following these changes to the regula-
tory systems. Finally, this Note strives to increase public awareness
as to the current level of FDA regulation of cosmetic products and
ingredients, as well as the cosmetic industry's role in establishing
additional regulatory methods.
I. BACKGROUND OF THE FDA
The FDA enforces three laws: the FDA Act, the FDA Moderniza-
tion Act of 1997, and the Bioterrorism Act of 2002.23 These laws
establish the spectrum of oversight granted to the FDA on products
ranging from drugs to cosmetics. Prescription drugs (New Drug Ap-
plications) are the most regulated of all products the FDA oversees,
22 id.
23 See generally Paul Hyman, U.S. Food and Drug Law and FDA - A His-
torical Background, in A PRACTICAL GUIDE TO FOOD AND DRUG LAW AND
REGULATION 15, 15-45 (Kenneth R. Pifia & Wayne L. Pines eds., 2d ed. 2002) (out-
lining the jurisdiction and the legislation governing the FDA's actions).
[Vol. 18:181
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requiring: "(1) preclinical investigation (laboratory and animal test-
ing); (2) clinical investigation (human testing); (3) FDA review of the
application; [and] post-marketing[,] [with] each of these phases in-
volv[ing] varying levels of FDA oversight.",24 Medical devices follow
closely behind prescription drugs in their level of FDA regulation.25
Three classes of medical devices exist, and regulation varies depend-
ing on the class, however, at its most lenient, the FDA regulates Class
I devices by applying "general controls, ' ' 6 which include "require-
ments for facility registration and product listing with [the] FDA, pre-
market notification ... maintenance of records and filing reports with
respect to device marketing experience, adherence to good manufac-
turing practices, ... and any distribution and use limitations [the] FDA
may impose." 27 Additionally, the FDA has the authority to ban Class
I devices "that present substantial deception or significant risks,
and/or to detain devices that are alleged to violate the FDA Act, pend-
,,28ing legal action. Class I, this least regulated category of devices,
includes elastic bandages, examination gloves and handheld surgical
instruments.29 Class II devices are subject to more stringent require-
ments, including performance standards, post-market surveillance and
patient registries, whereas Class Ell devices require pre-market ap-
proval.30
The FDA moderately regulates animal drugs and food additives,
with approval required before a company can introduce the products
into the U.S. market.3' General food products are regulated slightly
less than additives, while cosmetic products are the least regulated,
24 Geoffrey M. Levitt, The Drugs/Biologics Approval Process, in A
PRACTICAL GUIDE TO FOOD AND DRUG LAW AND REGULATION 89, 89 (Kenneth R. Pifia
& Wayne L. Pines eds., 2d ed. 2002).
25 See Edward C. Wilson, Jr. & Laurie A. Clarke, The Medical Device Ap-
proval Process, in A PRACTICAL GUIDE TO FOOD AND DRUG LAW AND REGULATION
127, 128 (Kenneth R. Pifia & Wayne L. Pines eds., 2d ed. 2002) (explaining that
medical devices that present a significant risk are subjected to strict review before the
FDA approves them for use).
26 id.
27 Id.
28 Id.
29 id.
30 Id. at 128-29.
31 See Levitt, supra note 24, at 122 (explaining the required showing of
safety and efficacy for animal drugs to be approved and that they are subjected to
post-approval regulatory oversight as well); see also Megan L. Foster & Daniel R.
Dwyer, The Regulation of Dietary Supplements, in A PRACTICAL GUIDE TO FOOD AND
DRUG LAW AND REGULATION 215, 215 (Kenneth R. Pifia & Wayne L. Pines eds., 2d
ed. 2002) (describing specific legislation that was enacted to regulate the niche area of
dietary supplements).
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requiring no independent review of safety studies, or any FDA ap-
proval prior to market introduction.32
A. Drugs vs. Cosmetics
Currently, a typical cosmetic product making its way to the U.S.
market, for example a face cream, may be classified by the FDA as
either a cosmetic or a drug. The product is appropriately classified as
a drug if it is "intended for use in the diagnosis, cure, mitigation,
treatment, or prevention of disease. .. and [if it is an] article[] (other
than food) intended to affect the structure or any function of the body
of man or other animals."33 The FDA is involved in examining drugs
through both preclinical and clinical investigation.34 The preclinical
phase is subject to good laboratory practices (GLPs), a specific FDA
regulation, published in the Code of Federal Regulations, which estab-
lishes specific requirements for certain aspects of laboratory practice,
subjects the laboratory to FDA inspectional oversight, and assigns
penalties for noncompliance. 35 "The primary purpose of the preclini-
cal investigation is to gather sufficient evidence about the proposed
new drug to proceed to the next regulatory stage" - clinical testing of
the product on humans.36 Prior to the commencement of clinical tri-
als, the producer must give the FDA formal notification, typically
called an Investigational New Drug (IND), in addition to submitting
other information, about the drug itself as well as the proposed clinical
trials.37 Clinical trials may begin only if the FDA does not object to
the information provided by the producing company. If the FDA
finds a problem with the application or IND, it can impose a "hold" on
32 See Foster & Dwyer, supra note 31, at 215 (explaining that food regula-
tions are less stringent than those enacted for dietary supplements); see also Thomas
J. Donegan, Jr. & Catherine C. Beckley, The Cosmetics Regulatory Process, in A
PRACTICAL GUIDE TO FOOD AND DRUG LAW AND REGULATION 149, 152-54 (Kenneth
R. Pifia & Wayne L. Pines eds., 2d ed. 2002) (describing the FDA's approach to
regulating the cosmetic industry and explaining that it is mostly a self-regulating
industry).
33 OFFICE OF COSMETICS & COLORS, U.S. FOOD & DRUG ADMIN., IS IT A
COSMETIC, A DRUG, OR BOTH? (OR IS IT SOAP?) (2002),
http://www.cfsan.fda.gov/-dms/cos-218.html [hereinafter Is IT A COSMETIC] (citation
omitted).
34 See Levitt, supra note 24, at 90-91 (describing the process and FDA over-
sight involved in preclinical and human clinical drug investigation).
31 id. at 90.
36 Id. at 91.
37 See id. at 91-92 (outlining the specific steps to be taken and information to
be provided to the FDA prior to beginning a human clinical investigation).
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the clinical trials, halting testing until the problem is resolved.38 The
application, among other things, must include:
[A] detailed "investigative plan" addressing ... the rationale
behind the planned clinical research, an outline of the pro-
posed approach, the types of clinical trials to be conducted, an
estimate as to the number of patients involved ... a discussion
of any significant anticipated patient risks based on toxico-
logical data ... [and] a commitment from the sponsor to con-
duct clinical trials under the supervision of an Institutional
Review Board (RB), and to follow all applicable rules and
regulations.39
In contrast, a product intended "to be rubbed, poured, sprinkled,
or sprayed on, introduced into, or otherwise applied to the human
body ... for cleansing, beautifying, promoting attractiveness, or alter-
ing the appearance," is a cosmetic.4n Currently, the FDA does not
mandate any pre-market regulation of cosmetics. 41 While manufac-
turers must test products and ingredients for safety, color additives are
the only cosmetic ingredients requiring pre-approval by the FDA.42
Because pre-approval is not required for other ingredients, the "FDA
enacted a labeling requirement for products where safety has not been
substantiated before marketing. 4 3 Cosmetic products with unsubstan-
tiated safety claims must label their products with the proper warning:
"[t]he safety of this product has not been determined.""
Under its limited authority, the FDA may regulate "adulterated"
and "misbranded" cosmetics after they have been sold in the U.S.
market. The federal government deems a cosmetic "adulterated" if:
"it bears or contains any poisonous or deleterious substance
which may render it injurious to users under the conditions of
use prescribed in the labeling thereof, or under conditions of
use as are customary and usual" [with an exception made for
hair dyes]; "it consists in whole or in part of any filthy putrid,
or decomposed substance"; "it has been prepared, packed, or
held under insanitary conditions whereby it may have become
38 Id. at 92.
39 Id.
40 IS IT A COSMETIC, supra note 33.
41 Donegan & Beckley, supra note 32, at 149.
42 id.
41 Id. at 150.
44id.
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contaminated with filth, or whereby it may have been ren-
dered injurious to health"; "its container is composed, in
whole or in part, of any poisonous or deleterious substance
which may render the contents injurious to health"; or except
for hair dyes, "it is, or it bears or contains, a color additive
which is unsafe within the meaning of section 721(a)" of the
FD&C Act.
45
The federal government considers a cosmetic "misbranded" if: (1)
its labeling is false or misleading; (2) in package form it does not bear
a label containing identification of its manufacturer, and an accurate
statement of the contents; or (3) its container is made to be mislead-
ing.46 The FDA justifies its "consumer choice" theory of protection
by mandating "an ingredient declaration to enable consumers to make
informed purchasing decisions. 4 7
Unfortunately, the labeling of a product as a drug rather than a
cosmetic, and the increased regulatory compliance such a label re-
quires provides an incentive for producers to avoid this categorization.
The resulting side-effect is an abundance of cosmetic products which
would be more appropriately labeled drugs. The incentive to avoid
the drug category, and its accompanying regulations, shows a failure
of the FDA's system of regulation, while doing a disservice to con-
sumers.
Even more problematic, some products, especially those with
more than one intended use, can meet both definitions and therefore
may actually be both a drug and a cosmetic product. Anti-dandruff
shampoo, which both cleans hair and treats dandruff, is an example of
drug/cosmetic hybrid product."8 The FDA determines a product's
intended use in three primary ways: (1) through claims made by the
product's producer; (2) through consumer perception of the product's
purpose; and (3) through ingredients in the product."9 If the producer
makes claims while advertising, labeling, or promoting the product
that show the intended use of the product is to "treat or prevent dis-
ease or otherwise affect the structure or functions of the human body,"
despite the fact that the product is marketed as a cosmetic, that prod-
45 OFFICE OF COSMETICS & COLORS, U.S. FOOD & DRUG ADMIN., FDA
AUTHORITY OVER COsMETIcS: WHAT DOES THE LAW SAY ABOUT COSMETIC SAFETY
AND LABELING? (2005), http://vn.cfsan.fda.gov/-dms/cos-206.html [hereinafter
FDA AUTHORrrY OVER COSMETICS] (citation omitted).
46 See id.
47 id.
48 IS IT A COSMETIC, supra note 33.
49 Id.
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uct should be labeled as a drug.50 Further, if consumers purchase the
product because they perceive (either through advertising or through
the product's reputation) that it will "treat or prevent disease or oth-
erwise affect the structure or functions of the human body," the prod-
uct should be labeled as a drug.51
B. Fair Packaging and Labeling Act
The Fair Packaging and Labeling Act (FPLA) was enacted to help
inform consumers and enable them to obtain accurate information as
to the contents of the products they purchase, keeping in mind that
informed consumers are essential to efficient functioning of a free
52
market economy. FPLA requires cosmetic labels to contain: the
identity of the commodity, the name and place of business of the
manufacturer, packer or distributor of the product, and the net quantity
of the product's contents, "separately and accurately stated in a uni-
form location upon the principal display panel of that label., 53 FPLA
makes it unlawful to distribute (or cause to be distributed) in com-
merce any commodity if it is contained in a package which does not
conform to the act's provisions. Unfortunately, many consumers do
not inspect their purchases for unsafe ingredients, and for an untrained
consumer, labeling products for the presence of unsafe contents does
not protect against the contents' risk.
The "FDA is not authorized to require recalls of cosmetics but
does monitor companies that conduct a product recall and may request
a product recall if the firm is not willing to remove dangerous prod-
ucts from the market without [the] FDA's written request."' A While
domestically produced cosmetics are not subject to FDA pre-market
approval, the FDA may inspect production facilities and product sam-
ples after receiving complaints of adverse reactions.55
C. Industry Self-Regulation
The cosmetic industry has made engaged in efforts to self-regulate
through programs established by both FDA and Cosmetic Toiletry and
Fragrance Association (CTFA). Currently, two programs exist to
regulate the cosmetic industry.
50 Id.
51 id.
52 Fair Packaging and Labeling Act, 15 U.S.C. § 1451 (2000).
" Id. § 1453(a)(1)-(2).
54 FDA AuTHoRrry OVER COSMETICS, supra note 45.
" See id.
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1. Voluntary Cosmetics Registration Program
In the early 1970s the FDA established the Voluntary Cosmetics
Registration Program (VCRP) at the request of the cosmetics indus-
try.56 At its inception, the VCRP created a system through which
companies could report post-market data to the FDA "on cosmetic
products being sold to consumers in the United States. 57 Originally
VCRP registration was comprised of three parts: (1) registration of the
location of the cosmetic manufacturing or packing establishment; (2)
filing of both the ingredient formulation of a cosmetic product already
on the market in the U.S. and any raw materials used in the product;
and (3) annual reporting of the number and type of adverse reaction
complaints from consumers or physicians.58 Since its creation, the
VCRP has been modified by the FDA.5 9 The current VCRP registra-
tion requires only: (1) registration of the location of the cosmetic
manufacturing or packing establishment; and (2) filing of the ingredi-
ent formulation of a cosmetic product already on the market in the
U.S.6° Raw material use and the annual reporting of adverse reactions
are no longer included in the VCRP.6'
Registration in the VCRP does not equate to FDA approval or en-
dorsement of a cosmetic producer, product, or materials used.62 Fur-
ther, only about 35 percent of eligible companies participate in
VCRP,63 meaning that nearly 65 percent of producing companies are
unregulated.
2. Cosmetic Ingredient Review
In the early 1970s, Congress considered legislation to amend the
FDA Act, which would have required pre-market safety testing for
cosmetic products similar to that currently required for drugs.64 Since
the FDA lacked the resources necessary to inspect facilities and re-
56 M.V. Waleski, L.K. Parker & D.C. Havery, Abstract to History of FDA's
Voluntary Cosmetics Registration Program, FDA SCI. F., available at
http://www.accessdata.fda.gov/scripts/oc/scienceforum/sf2006/Search/preview.cfm
?abstract id = 1102&backto =author.
57 Id.
58 Id.
59 Id.
60 Id.
61 Id.
62 Foulke, supra note 4.
63 Id.
64 Wilma F. Bergfeld et al., Safety of Ingredients Used in Cosmetics, 52 J.
AM. ACAD. DERMATOLOGY 125, 125 (2005).
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view safety data, Congress did not institute this legislation. Instead,
the cosmetic industry established their own industry-wide self-
66regulatory program.
The Cosmetic Ingredient Review (CIR) program sponsored by the
Cosmetic, Toiletry and Fragrance Association67 (CTFA), is an indus-
try sponsored self-regulation program implemented by a panel of sci-
entific and medical experts who evaluate cosmetic ingredients for
safety. 68 "The CIR mission statement calls for the thorough review
and assessment of the safety of ingredients used in cosmetics in an
open, unbiased, and expert manner .. ,,6 with results and detailed
reviews of available safety data published in "peer-reviewed scientific
literature. 7 °
The CIR catalogues cosmetic ingredients in an International Cos-
metic Ingredient Dictionary and Handbook, and reviews the ingredi-
ents based on a priority system determined by the frequency of use
and potential biologic activity.7  The CIR Expert Panel reviews cos-
metic ingredients regularly, and classifies the ingredients into catego-
ries, including: "safe as used, safe with qualifications, unsafe, and
insufficient data., 72 The ingredients as well as the Expert Panel's
findings are listed on the CIR website.73
Out of nearly 1200 individual cosmetic ingredients reviewed, the
cosmetic industry through the CIR Expert Panel, has identified limita-
tions on 33 percent of ingredients reviewed, and has placed an alert on
another 9 percent.74  Further, "a handful of ingredients have been
identified [by the Expert Panel] as unsafe for use in cosmetics. 75
Unfortunately, the CIR is unable to review every cosmetic prod-
uct on the market. CIR review is voluntary and as such only regulates
65 See id.
66 Id. at 126; see also Donegan & Beckley, supra note 32, at 150 (noting that
the cosmetic industry works alongside the FDA to ensure the safety of their products).
67 The Cosmetic, Toiletry and Fragrance Association is also referred to by
some as the Personal Care Products Council.
See http://www.personalcarecouncil.org/ (last visited March 31, 2008).68 Foulke, supra note 4.
69 Bergfeld et al., supra note 64, at 126.
70 Id.; see also Foulke, supra note 4.
71 Bergfeld et al., supra note 64, at 126.
72 Id. at 128.
73 Id.; see also Cosmetic Ingredient Review, Cosmetic Ingredient Findings:
1976 - Current, http://www.cir-safety.org/findings.shtml (last visited Sept. 16, 2007)
(listing the CIR's findings with respect to investigations on cosmetic ingredient
safety).
74 Bergfeld et al., supra note 64, at 131.
75 Id.
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products submitted by their manufacturers for review, 76 "The Envi-
ronmental Working Group's report Skin Deep states that 89 [percent]
of ingredients used in personal care products have not been evaluated
for safety by the C1R, the FDA, nor any other publicly accountable
institution. 77 Without the CIR, however, no systematic examination
of the safety of individual cosmetic ingredients would exist, as the
FDA currently has no statutory authority to require that products be
submitted for any type of pre-market review. 78 This industry insti-
tuted program is currently the only safety testing of its kind for U.S.
cosmetic products.
II. MORE STRINGENT REVIEW NEEDED
The level of review currently in place in the U.S. is much more
lenient than that of other countries, and as a result, some U.S. states
have enacted their own more stringent standards. Products from an
array of categories also regulated by the FDA are subject to much
stronger, mandatory testing, leading U.S. consumers to assume that
cosmetic products are regulated in a similar fashion. 79 The discrep-
ancy between the perception of American consumers and the level of
regulation currently in place for cosmetic producers necessitates the
development of a stronger U.S. regulatory system.
A. International Regulation
Countries outside the U.S. have recognized the inherent risk in
cosmetic ingredients, and as such established stringent review re-
quirements for cosmetic products. The EU banned the sale of cosmet-
ics or personal care products that contain any ingredients on a list of
more than one-thousand chemicals known or suspected of causing
cancer, genetic mutations, or birth defects;80 in the U.S., the FDA has
banned only nine such ingredients.8  The EU also mandates, "[A]
compilation of information on each cosmetic product (dossier) must
be kept readily accessible for inspection by the competent authorities
76 Id. at 126.
77 Think Before You Pink, Corporate Cover-Up: The Regulation of Our
Cosmetics, http://www.thinkbeforeyoupink.org/Pages/CorporateCoverUp.html (last
visited Sept. 29, 2007) (citation omitted).
78 See Foulke, supra note 4; see also Kawalek, supra note 5, at 56.
79 See Kawalek, supra note 5, at 56 (reporting that many similar products are
FDA tested, while cosmetics are not).
80 See Stiffler, supra note 10; Walgreen Co., SEC No-Action Letter, 2006
SEC No-Act. LEXIS 638, at *9 (Oct. 13, 2006) (citation omitted).
81 Walgreen Co., SEC No-Action Letter, 2006 SEC No-Act. LEXIS 638, at
*11; Stiffier, supra note 10.
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of the Member State concerned at the address specified on the cos-
metic package. 82 This dossier:
should contain information on the qualitative and quantitative
composition of the products, its physico-chemical and micro-
biological specifications, the method of manufacture, evalua-
tion of its safety for human health, the name, address and
qualifications of the safety assessor, existing data on undesir-
able effects on human health, proof of the effect(s) claimed
and data on any animal testing performed relating to the de-
velopment or safety evaluation of the product or its ingredi-
ents.83
The dossier is called a Technical Information File (TIF) and usu-
ally consists of four parts:
(1) An administrative dossier: [tirade name of the product and
responsible company, manufacturer or distributor[;] [p]roduct
category[;] [i]ntegral composition of the product[;] [and]
identification of persons with ultimate responsibility [for the
product]. (2) An ingredients dossier: [i]dentify(ies), sup-
plier(s) and composition(s) of the ingredients[; [d]etails on
manufacturer(s) and supplier(s) of the ingredients[;]
[pihysico-chemistry and microbiology of the ingredients...
[;] [t]oxicity data . . . [;] [f]irst aid measures[;] [r]isk and
safety instructions ... [;] [l]ist of animal tests performed with
the ingredient. (3) A finished product dossier: [flabrication of
the product with place(s) of manufacturing, methodology,
identification of person responsible for manufacturing[;
[s]tability of the product including physical and microbiologi-
cal stability[;] [pihysico-chemical properties and microbi-
ological data on the finished product including examina-
tions[;] [s]afety data concerning the finished product includ-
ing an overview of the toxicological data of the ingredients;
the communication done with the national competent authori-
ties and the poison control centres [sic.]; toxicological animal
testing performed on the finished product; toxicological tests
using alternative methods; human tests performed on the fin-
ished product; an undersigned safety evaluation with the iden-
82 Marleen Pauwels & Vera Rogiers, Safety Evaluation of Cosmetics in the
EU Reality and Challenges for the Toxicologist, 151 TOXICOLOGY LETTERS 7, 9
(2004).
83 id.
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tification of the safety assessor and the appropriate creden-
tials[;] [e]fficacy of the finished product . . .[;] [p]ackaging
and labeling . . (4) Follow-up dossier of the market: a good
functioning post-market complaint system, where consumers
can communicate eventual complaints must be installed. All
undesirable effects on human health reported during use of
the product and their follow-up by the responsible manufac-
turer or marketer, must be added to the dossier.
84
Although the EU has established a more in depth system of regu-
lation than that currently existing in the U.S., compiling a list of un-
safe ingredients is an imperfect, and temporary, solution to a larger
problem. A list format is effective only when the list contains every
possible dangerous cosmetic ingredient. With the passage of time,
however, lists become out of date, and as such, the system of regula-
tion is ineffective.
The EU's TIF dossier program is a more effective regulatory
mechanism than the U.S.'s ingredient list or, post-market complaint
system. This information, however, is only effective if consumers
know of its existence and can easily access and understand it. If con-
sumers are unaware of data identifying undesirable health effects sur-
facing after a product's use in the market, they are unable to protect
themselves, thereby making the data irrelevant as a consumer protec-
tion device. Currently in the U.S., the CTFA is in the process of initi-
ating a new program, the Consumer Commitment Code (CCC).85
CCC, which will include a dossier program similar to that established
by the EU, will make safety information more easily accessible to the
FDA. To participate in the program, companies must provide a safety
information summary to the FDA upon request. This summary will
list information including raw material specifications, particle size,
and "a statement that the product's safety has been substantiated. 86
While CCC is a step in the right direction, the CTFA has no regu-
latory authority to mandate FDA inspection, pre-market approval, or
cosmetic manufacturer participation in the program. The EU TIF
dossier program mandates participation by all cosmetic producers in a
program which already outlaws the use of over one-thousand harmful,
or potentially harmful ingredients. Although the EU program is not
84 Id. at 9-10.
85 Comment from Envtl. Working Group, to U.S. Food & Drug Admin., A
Survey of Ingredients in 25,000 Personal Care Products Reveals Widespread Use of
Nano-Scale Materials, Not Assessed for Safety, in Everyday Products (Oct. 10, 2007),
http://www.ewg.org/node/21738.
86 Id.
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the ideal method of regulation, at the very least, the EU has the au-
thority to mandate compliance. The CTFA can not require cosmetic
producers to participate in the CCC program.
Voluntary systems in the U.S. like CCC, VCRP and CIR will not
create the level of effective regulation necessary to effectively protect
consumers. One main problem with the current FDA regulatory
scheme is that U.S. consumers believe that products are approved by
the FDA prior to market introduction. John Bailey, director of FDA's
Office of Cosmetics and Colors has said, "[clonsumers believe that 'if
it's on the market, it can't hurt me' ... [a]nd this belief is sometimes
wrong. ,87 In fact, "[t]he ingredient list on a cosmetic container is the
only place where a consumer can readily find out the truth about what
he or she is buying."8 8 Consumers can check the listing to identify
substances they wish to avoid, however, if they do not know which
substances they should avoid, the ingredient list provides only an illu-
sory protection against the risk cosmetic ingredients pose.
B. Individual State Regulation
In the absence of strong FDA regulations, some U.S. states have
heightened their rules, enacting stronger regulations than those of the
FDA. California lawmakers, for example, adopted the Safe Cosmet-
ics Act of 2005 (SCA).89 SCA is a response to independent testing in
the U.S. and the EU, both of which determined that some cosmetic
products contain substances known or suspected to cause cancer and
reproductive toxicity.90 Further, because neither the FDA nor the
State Department of Health Services required pre-market safety test-
ing, review, or approval of cosmetic products, California legislators
created the SCA to fill this gap. The SCA requires cosmetic manufac-
tures to provide the state with a list of product ingredients which can
cause cancer or reproductive harm.91 SCA concludes:
[g]iven the presence of substances in cosmetic products that
cause cancer and reproductive toxicity, the heavy use of these
products by women of childbearing age, the significant expo-
sure to these products in occupational settings such as nail and
beauty salons, the adverse impacts of these substances on hu-
87 Carol Lewis, Clearing Up Cosmetic Confusion, FDA CONSUMER, May-
June 1998, http://www.fda.gov/fdac/features/l1998/398_cosm.html.
88 Id.
89 Stiffier, supra note 10.
90 California Safe Cosmetics Act of 2005, 2005 Cal. Legis. Serv. ch. 729, §
1 (a) (West).
91 Id. § 1(b).
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man health, the inadequate information about the presence of
these substances in products or the extent of their impacts,
and the availability of alternatives to the use of these sub-
stances, it is in the interest of the people of the State of Cali-
fornia to take steps to ensure that cosmetic products sold and
used in the state can be used safely.
92
This heightened regulation by the California legislature is another
step in the right direction, however, SCA only requires that companies
provide the state with a list of potentially harmful ingredients. SCA
does not require any form of testing prior to market introduction. As
explained above, lists of prohibited ingredients do not regulate effec-
tively. When new, yet harmful, ingredients are developed, consumers
will not be protected against them simply because they were not in-
cluded on an already developed list of harmful ingredients. Instead, a
system which requires testing and post-market reporting of complica-
tions is more effective.
The SCA legislation is, however, beneficial because in mandating
disclosure of ingredients which can cause cancer or reproductive
harm, the legislation encourages cosmetic producers to test and learn
more about their ingredients. Such testing is beneficial to the industry
and to consumers, and it has been a priority of scientists and research-
ers calling for the creation of a "cosmeceutical" category,93 yet it has
frequently been avoided by cosmetic producers aiming to avoid a
"drug" label for their products.
94
IH. PROPOSED REGULATORY CHANGES
The level of regulation currently provided by the FDA is inade-
quate. A purely reactive system of product regulation, like the one
currently in place, is ineffective because it necessitates the existence
of a problem before producers are sufficiently incentivized to find a
solution. Although the FDA definition of a cosmetic product clearly
differs from the FDA definition of a drug, the actual distinction be-
tween cosmetic products and drugs has blurred over time and many
products could fall into a hybrid category of "cosmeceuticals." 95
These products may have multiple purposes, however the current in-
centive for producers to categorize products as cosmetics puts Ameri-
92 Id. § 1(j).
93 Lazarus & Baumann, supra note 7.
94 id.
95 See Natasha Singer, A Word from Our Sponsor, N.Y. TIMES, Jan. 25, 2007,
at G1.
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can consumers at risk by avoiding the pre-market testing and FDA
approval required of drug products.
"The public at large and a wide array of interest groups in Ameri-
can society demand the presence of FDA in the marketplace .... ,
96
FDA experts argue that "changes in FDA's external environment and
in the demands placed on [it] to protect and promote public health will
require [the] FDA to re-examine the way it works in relation to indi-
,,97viduals and private institutions in society. The time for re-
examination is upon us. Despite demands for FDA presence in the
marketplace, the FDA may be required to partner with industry lead-
ers in order to fund any regulatory improvements it makes. A number
of potential solutions exist with varying levels of FDA involvement.
Investigation into the FDA regulatory process of prescription drugs as
well as the dental industry's self-regulatory practices may lead to an
appropriate regulatory solution for cosmetic products.
A. Creation of A "Cosmeceutical" Category Under the FDA
One potential change the FDA could institute would be to for-
mally create a category for "cosmeceutical," products. The FDA
could adopt the current industry definition of "cosmeceutical," and
classify cosmetic products which possess the appropriate characteris-
tics under this title.98 In doing so, the FDA should not require pre-
market testing and FDA approval for all cosmetic products similar to
the process currently required for drug products. Instead, the FDA
should mandate this more stringent level of testing only for products
falling under the new "cosmeceutical" classification.
The positive effect of this policy is that development of a "cosme-
ceutical" category would ensure protection of consumers against
products possessing properties similar to some drugs, products which
currently require no pre-market safety testing. The negative effect of
creating this category is the cost to the FDA; as already stated, the
FDA's budget leaves very little room for new obligations. While the
creation of a "cosmeceutical" category would cost less to implement
than full-scale testing and pre-market approval of all cosmetic prod-
ucts, the additional cost to the FDA of regulating "cosmeceutical"
products may still be unmanageable.
96 Michael R. Taylor, Fundamental Issues Facing 21st Century Regulation,
in A PRACTICAL GUIDE TO FOOD AND DRUG LAW AND REGULATION 323, 324 (Kenneth
R. Pifia & Wayne L. Pines eds., 2d ed. 2002).
97 Id. at 325.
98 See Lazarus & Baumann, supra note 7 (defining "cosmeceutical" as "a
cosmetic product that claims to or has been found to have biologic activity").
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Another negative effect of this policy change is the fact that crea-
tion of a "cosmeceutical" category on its own does nothing to protect
consumers who purchase and use the products still classified as cos-
metics. These cosmetic products would receive no additional safety
testing, and thus would remain minimally regulated. Despite these
negative aspects, the creation of a hybrid, "cosmeceutical" category
would provide a higher level of testing for products containing "cos-
meceutical" properties, thereby providing a higher level of safety to
the American public.
B. Requirement of FDA Testing and Pre-Market Approval
Another regulatory change the FDA could enact for all cosmetic
products would be mandatory testing and pre-market approval similar
to that currently required of drugs. Mandating this level of testing for
cosmetic products would ensure that every ingredient and product is
tested for safety and efficacy prior to its entrance into the U.S. market.
This option would protect consumers from ingredients which may
cause physical harm, or products which fail to perform as their pro-
ducers claim.
Mandating testing and pre-market approval would be a perfect so-
lution if the FDA had adequate funding to oversee such research.
Unfortunately, the FDA has seen its budget dwindle in recent years. 99
"[F]unding for drug safety is 'especially inadequate,"' and the "FDA's
food division budget . . . is 'even more dire'. . . ."'0 The funding
situation has become so strained that the FDA's food division, the
department "which tries to keep tainted foodstuffs from supermarket
shelves" cut its headquarter workforce from 950 to 850 employees in
2006. ' ° ' This funding situation led Food Division director Robert
Brackett to state, "[the FDA] has been presented with unique chal-
lenges, and we will not be able to take on the same large number of
objectives we have identified in previous years.' 1 2 As a result of the
changing economy, including the expansion of global trade, "the
number of shipments of foreign-produced regulated products [in-
creased] from about 1.5 million in 1992 to 6 million in 2000."1°3 As
such, the "FDA's investigators are now able to sample less than 1
99 See Los Angeles Times Examines FDA Funding Levels, MED. NEWS
TODAY, Oct. 12, 2006, http://www.medicalnewstoday.com/articles/53845.php.
10o Id.
101 Id.
102 Id.
103 See FDA's GROWING RESPONSIBILITIES, supra note 1, at 5-6.
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percent of all food offered for imports."'' °4 The FDA funding situation
is worse now than it has ever been before.10 5
With FDA funding in short supply, implementation of mandatory
testing and pre-market approval for all cosmetic products is simply
not feasible. The FDA cannot mandate and adequately implement
such testing at the levels currently in place for drug products. As
such, the FDA should consider less costly methods of regulating the
cosmetic industry.
C. FDA Promotion of Current Regulatory Practices to the American
Public
Consumers believe that the cosmetic products currently on the
market are adequately regulated and approved by the FDA as safe and
effective, yet this belief is unfounded. 0 6 Therefore, if the regulatory
system is not strengthened., at the very least, the FDA must ade-
quately inform American consumers of the current lack of oversight
and approval in the cosmetic industry. While the FDA may effec-
tively pass on regulation and other responsibilities to the cosmetic
industry, ultimately, the responsibility for oversight rests with the
FDA itself.107
One potential method for informing consumers of the current lack
of regulation of cosmetic products would be to display warning in-
formation in all places those products are sold. Such information
should clearly state a message to the effect of:
The FDA prohibits misbranded and adulterated cosmetics,
however, the FDA does not subject cosmetics to pre-market
testing or approval. Cosmetic products-and the ingredients
used in their formulation-should be tested by their manufac-
turer for safety, however, the safety of some products cannot
be substantiated. As such, any product whose safety cannot
be substantiated by its manufacturer will display a warning on
104 id.
105 See Los Angeles Times Examines FDA Funding Levels, supra note 98.
106 See Lewis, supra note 87 (reporting that confused cosmetic consumers
wrongfully believe that they are protected by the FDA); see generally Kawalek, supra
note 5 (discussing consumers' mistaken beliefs in the safety of marketed cosmetic
products).
107 See Taylor, supra note 96 (describing the general public's expectation that
the products and devices made available for use and purchase are safe).
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its label stating this fact. Please read all cosmetic product la-
bels carefully and thoroughly.
10 8
The FDA could also communicate a similar message through
television and radio commercials, newspaper, magazine and billboard
advertisements.
Additionally, if the FDA utilizes this method to inform the
American public of the current lack of oversight in the cosmetic in-
dustry, it should require manufacturers of products with unsubstanti-
ated safety to include in their packaging a warning insert containing
the message above, as well as a message to the effect of the following.
The safety and/or efficacy of the product you have purchased
has not been substantiated by the product's producer, or by
the FDA. Please take caution in using this product. If un-
used, you may return this product to the store where it was
purchased, or to its manufacturer for a full refund. °9
One benefit of this option-informing the American public of the
current lack of oversight, or approval of the cosmetic industry-is that
the cost to the FDA is far less than in the options discussed above.
Further, this option would be beneficial if used in conjunction with a
unified regulatory program adopted by the cosmetic industry. Al-
though there would be some cost associated with advertisements and
warning inserts, the FDA could share this cost with the cosmetic in-
dustry, while working with producers of cosmetic products to develop
and distribute informational materials. Considering current FDA
budgetary constraints, this would benefit the agency and would give
cosmetic producers input in creating the warning advertisements and
inserts.
D. Industry Sponsored Seal of Approval Program
In light of the FDA's current budgetary constraints, it is appropri-
ate, and necessary, for the FDA to look to the cosmetic industry to
assist in formulating and sponsoring a new review process. The FDA
could join forces with the cosmetic industry to develop a new regula-
tory system, or the industry could independently create a program
similar to those in use in other industries.
The American Dental Association (ADA) established a Seal of
Acceptance (Seal) program in 1930. 110 The Seal program formulated
108 Id.
109 Id.
110 Am. Dental Ass'n, ADA Seal of Acceptance: Frequently Asked Questions
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rigorous guidelines for testing and advertising dental products."' A
manufacturer applying for the Seal must supply the ADA with objec-
tive data from "clinical and/or laboratory studies that support the
product's safety, effectiveness and promotional claims."" 2 A manu-
facturer must also conduct clinical trials as required in strict compli-
ance with ADA guidelines." 3 A manufacturer must also "[p]rovide
evidence that manufacturing and laboratory facilities are properly
supervised and adequate to assure purity and uniformity of the prod-
uct, and that the product is manufactured in compliance with Good
Manufacturing Practices."' 14 Finally, a manufacturer must submit all
advertising and promotional claims, all patient education materials for
review and approval by the ADA, be in compliance with the ADA's
standards for accuracy and truthfulness in advertising and submit in-
gredient lists and other pertinent product information for review and
approval." 
5
Over 100 consultants, ADA staff scientists, and members of the
ADA's Council on Scientific Affairs review the safety and efficacy
oral care products seeking the ADA Seal." 6 The ADA may conduct
or request additional product testing, and will only award a product
the ADA Seal after it has been proven safe and effective. 17 Over 400
products carry the mark of this voluntary Seal program." 8 Participat-
ing manufacturers contribute significant resources to evaluate, test,
and market products eventually receiving the Seal." 9
The ADA Seal of Acceptance is typically awarded for a five-year
period, after which manufacturers must reapply in order to continue
using the Seal.' 20 If "the composition of an [a]ccepted product
changes, the company must resubmit the product for review and ap-
proval before it is marketed with the Seal."' 12' A product must con-
tinue to meet these requirements "as long as [it[ bears the ADA
Seal." 122
(FAQ), http://www.ada.org/ada/seallfaq.asp (last visited Oct. 5, 2007).
1' Id.
112 Id.
'13 Id.
14 Id.
115 Id.
116 Id.
'7 Id.
118 Id.
119 Id.
120 Id.
121 Id.
122 Id.
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As stated above, the ADA reviews all advertising claims for prod-
ucts bearing the Seal. 123 The ADA permits only those claims that can
be supported by appropriate clinical and/or laboratory studies and
scientific data. 124 The ADA Seal was designed to assist the public (as
well as dental professionals) in making informed decisions regarding
the safety and efficacy of dental products. 125 "Market research has
shown that the ADA seal on a product directly affects the purchase
decisions of consumers." 1
26
The cosmetic industry should consider instituting its own en-
dorsed approval program. The CTFA should establish oversight for
the cosmetic industry's approval program, drawing from its involve-
ment in CIR review. Similar to CIR review, a cosmetic industry ap-
proval program should be purely voluntary. Involvement by major
cosmetic producers should, as it has with the ADA Seal program, mo-
tivate other producers to participate. Unlike the CIR program, which
lists results and reviews of safety data in peer-reviewed scientific lit-
erature,127 a cosmetic industry approval program should ensure the
mark of approval appears prominently on all packaging so that it is
visible to consumers. Further, a cosmetic industry approval program
would differ from CIR review in that the approval program should
conduct a safety and efficacy review of cosmetic products in the order
they were submitted to the overseeing body. Additionally, unlike CIR
review, the application for a cosmetic industry Seal of Approval
should result in either approval or disapproval. This would avoid a
confusing rating system thereby helping consumers remain informed
about their cosmetic purchases. Finally, cosmetic producers must be
free to sell their products to consumers prior to, or without receiving,
the cosmetic industry's Seal of Approval. As with the ADA Seal pro-
gram, participation must be voluntary, but consumers are likely make
purchasing decisions based on whether a product has industry ap-
proval.
128
123 Id.
124 id.
125 Id.
126 id.
127 Bergfeld et al., supra note 64, at 126.
128 See Am. Dental Ass'n, supra note 110.
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E. FDA Institution of Shared-Fee Practices Similar to the Prescription
Drug User Fee Act
As stated above, the current state of the FDA's budget is such that
the agency cannot adequately fund new regulations.1 29 As such, the
FDA could consider instituting a shared-fee practice, requiring indus-
try assistance in funding any heightened level of regulation.
The FDA has had shared-fee programs in the past, most notably
after Congresses' 1992 passage of the Prescription Drug User Fee
Act. 130 Prior to 1992, taxpayers alone supported the costs of prescrip-
tion drug review by the FDA.13 ' At this level of funding, it took the
FDA an average of 30 months to review a new medication. 132 After
the 1992 passage of the Prescription Drug User Fee Act (PUDFA), the
FDA collected fees from drug producers to support review.133 Corn-
panies seeking FDA approval of a new drug or biologic must now
submit an application along with a fee to the FDA.'3 In the years
since PUDFA was implemented, the FDA has been "able to hire addi-
tional reviewers and support staff who have helped reduce the median
review time for drugs to 12 months[ ,]... [and] breakthrough products
are now reviewed in 6 months or less."'' 35 This shortened review has
increased "the number of new drugs approved in a year... [to] almost
40 percent ... ,,136
"The combination of efficient reviews and high product standards
have made the United States the country of choice for the world's
leading drug manufacturers who want to introduce new medicines.' 37
Prescription drug companies pay annual fees "for each manufacturing
establishment and for each prescription drug marketed."' 138 The FDA
also assesses user fees for producers of animal drugs 139 and medical
devices to support those respective review processes.
40
129 See Los Angeles Times Examines FDA Funding Levels, supra note 99.
130 U.S. Food & Drug Admin., Prescription Drug User Fees - Overview,
http://www.fda.gov/oc/pdufa/overview.html (last visited Sept. 29, 2007) [hereinafter
Prescription Drug User Fees].
131 Id.
132 FDA's GROWING RESPONSIBiLrrIES, supra note 1, at 3.
133 Prescription Drug User Fees, supra note 130.
134 Id.
05 FDA's GROWING RESPONSIBIIJTIES, supra note 1, at 4.
136 Id.
137 Id.
138 Prescription Drug User Fees, supra note 130.
139 Animal Drug User Fee Act of 2003, 21 U.S.C.S. § 379j-12 (LexisNexis
2006).
140 Medical Device User Fee and Modernization Act of 2002, 21 U.S.C.S. §
379j (LexisNexis 2006).
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The FDA should consider instituting a shared-fee practice among
cosmetic producers in order to fund an expanded safety review pro-
gram. Such a program would require cosmetic producers to pay an-
nual fees for each manufacturing establishment, as well as submit an
application and new product fee for each new product they wish to
add to the U.S. market. With these fees, the FDA would have ample
resources to hire cosmetic product reviewers and support staff. These
reviewers would test the safety and efficacy of each product for which
a company applied for market admission.
Negative aspects of this program include prolonged delays in the
entrance of products into the U.S. market. In the current system,
products can enter into the U.S. market as soon as producing compa-
nies decide they are ready to sell the product. With an FDA run sys-
tem of review like the one described above, however, producers must
wait until FDA reviewers have approved each product before market-
ing and selling the cosmetic to the public. The positive effect of this
delay is that American consumers would be able to select cosmetic
products knowing that the ingredients and the product passed safety
and efficacy review.
F. Industry Consolidation of Review Programs
The most practical, and potentially the most effective regulatory
change would include several of the options discussed above. The
cosmetic industry should create an industry-wide Seal of Approval
program with a fee-sharing element, to fund the program. To main-
tain involvement, the FDA should participate in the approval program,
either by providing a representative to serve as a reviewer, or by pub-
licizing the level of current regulatory practices to the American pub-
lic. The FDA could promote the level of regulation through adver-
tisements on television and in print media, as well as though cosmetic
package inserts and in-store advertising.
The cosmetic industry's approval program should be organized by
the CTFA, and should be voluntary. The approval program should
consist of an application process, where cosmetic producers submit
product ingredients, specifications, and advertising to a review board.
The board would examine testing completed by the producer, and
would re-test to the extent necessary. After testing and evaluating the
product, the review board would either approve or reject the product.
If a product is approved, the industry's stamp of approval can appear
on the packaging and advertising for that product.
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As with the ADA Seal program, involvement by major cosmetic
producers should motivate smaller producers to participate.' 41 After
gaining familiarity with the program, consumers are likely to begin
looking for the approval marking on cosmetic products. Meanwhile,
producers who choose not to participate in the approval program will
still be able to sell and market their products. Consumers will simply
know that their products have not been approved by the industry's
review board.
The CTFA should institute a shared-fee practice similar to that
used by the FDA with prescription drug manufacturers, in order to
fund this expanded safety review program. Cosmetic producers
should be required to pay annual fees for each manufacturing estab-
lishment, and should be required to submit an application and new
product fee for each new product they wish to add to the U.S. market.
The CTFA could then use these fees to hire cosmetic product review-
ers and support staff, and may additionally choose to contribute some
of the revenue to the FDA for use in promoting the regulatory system.
As discussed previously, negative aspects of this program include
prolonged delays in the entrance of products into the U.S. market.
Without regulation, products can currently enter the U.S. market as
soon as companies decide they are ready to sell a product. However,
with an industry run system of review like the one described above.,
producers must wait until the industry panel approves each product
before marketing and selling the cosmetic to the public. A positive
result is that American consumers will be able to select cosmetic
products knowing that they and their component ingredients have
been tested for safety and efficacy.
If the cosmetic industry does not institute a Seal of Approval pro-
gram, the next option to consider is the consolidation of industry-
regulated review programs. The cosmetic industry, through sponsor-
ship by the CTFA and endorsement by the FDA, should consolidate
the original VCRP142 established by the FDA in the early 1970's, the
CIR currently in place, and the CCC currently under development by
the CTFA.
The original VCRP, which included three parts: registration in-
formation for the manufacturing or packing establishment, informa-
tion regarding the ingredient formulation and raw material usage in
cosmetic products, and annual reporting of adverse reactions, would
have to be re-adopted by the cosmetic industry to replace the abbrevi-
141 See Bergfeld et al., supra note 64, at 131 (stating that personal care prod-
uct companies are committed to the CIR program).
142 Voluntary Cosmetics Review Program, discussed infra section I.C. 1.
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ated version currently in operation. Further, this program would have
to be consolidated with two other programs; the CIR currently in prac-
tice, which through its Expert Panel provides review and assessment
of the safety of ingredients used in cosmetics, and the CCC currently
under development by the CTFA, which will include a dossier pro-
gram similar to that established by the EU. The compilation of these
three programs would maximize the amount of information gathered
from cosmetics producers, and will in-turn maximize the amount of
information available to consumers.
It is not necessary for the FDA to run the consolidated review
program, especially considering budgetary constraints which might
make such involvement impossible. As such, registration for the
combined program would not be mandatory unless Congress passes
legislation requiring all cosmetic producers to participate. Absent
such legisltion, registration should be encouraged of all cosmetic
producers. To incentivize cosmetic producers to register and partici-
pate in the combined review program, products having successfully
completed review must have a specific designation or logo on their
packaging. This designation would inform consumers that the product
has undergone safety testing and received industry approval.
The FDA should, however, maintain the oversight of cosmetic
regulation as mandated by the FDA Act.1 43 The best way for the FDA
to fulfill its duty to regulate cosmetics is by endorsing the new pro-
gram and promoting the new regulatory practices to the American
public. In conjunction with a unified cosmetics industry and com-
bined review program, the FDA should enact the promotion and ad-
vertisement changes analyzed above. The FDA should create a warn-
ing message for display in stores selling cosmetic products, in order to
inform consumers about the current state of the regulatory system.
The FDA should also write a warning message for inclusion in the
packaging of products producers have not submitted for testing
through the consolidated review program. Finally, the FDA should
create advertisements for television, radio, newspapers and maga-
zines, to inform the American public about the new consolidated re-
view program, its requirements and protections. Together these prac-
tices should inform American consumers of the safety regulations
currently in effect, allowing consumers to make informed decisions
about cosmetic purchases.
143 See Hyman, supra note 23, at 21-25 (describing the enactment of the Fed-
eral Food, Drug, and Cosmetic Act in 1938 that brought regulation of cosmetics and
therapeutic devices under the FDA's jurisdiction).
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CONCLUSION
American consumers have a heightened sense of FDA regulation
generally because they are aware of drug recalls and food source con-
taminations, which take center stage on the nightly news. As a result
of this awareness, many American consumers mistakenly assume that
the FDA, regulates all products in a uniform fashion. 144 This is
clearly not the case. As such, the FDA has a responsibility to inform
American consumers about the actual level of regulation of cosmetic
products.
Additionally, the cosmetic industry, through the CTFA, has as-
sumed a great deal of responsibility for providing safety testing and
strengthened review of products, particularly where the FDA has
fallen short. The industry should be commended for their efforts,
however, the system of regulation currently in place is imperfect. To
make the regulation they offer as effective as possible, one of the two
options described above must be implemented. The industry must
either create a Seal of Acceptance program similar to that created by
the ADA, or the industry-sponsored review systems currently in effect
should be consolidated as explained above. The selection of one of
these two options, coupled with endorsement and advertising provided
by the FDA, the cosmetic industry will be able to provide the Ameri-
can public with the increased level of safety testing they expect. Fur-
ther, the FDA's advertising and promotion of the selected review sys-
tem and the testing methods in existence will further inform American
consumers as they make purchasing decisions. To leave consumers
without such testing and information subjects them to the mercy of a
system that currently leaves them uninformed and unprotected.
'4 See id.
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